Drug Trial Radar · NCT04005417
Meta-analysis of Stannous Fluoride Dentifrice and the Effects on Dentine Hypersensitivity
Last checked: Nov 20, 2026Latest source record: Jul 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,036
Actual
Start
Jan 8, 2018
Primary completion
Nov 30, 2018
Study completion Nov 30, 2018
Sponsor
- Lead sponsor
- Procter and GambleIndustry
- Sponsor type
- Industry
- First posted
- Jul 2, 2019
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this 11 study analysis was to compare the effect of bioavailable stannous fluoride (SnF2) on dentine hypersensitivity versus a positive or negative control dentifrice.
Conditions
- Dentine Hypersensitivity
Interventions
Stannous fluoride dentifriceDrug
Stannous fluoride (0.454%) dentifrice
Positive control dentifriceDrug
Positive control dentifrice containing potassium nitrate or arginine.
Negative control dentifriceDrug
Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline Air ChallengeTime frame: Up to 8 weeks
- Change from Baseline in Tactile ThresholdTime frame: Up to 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Multiple P&G Investigation Clinical Sites
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.